LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on February 1, 2021, the Company granted non-qualified stock options to purchase an aggregate of 57,550 shares of the Company’s common stock to four newly hired employees. These grants were made pursuant to the Company’s 2021 Inducement Stock Incentive Plan, were approved by the Company’s Inducement Grant Subcommittee of the board of directors, and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

View post:
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)